<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409667</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457A3302</org_study_id>
    <nct_id>NCT02409667</nct_id>
  </id_info>
  <brief_title>Plaque Psoriasis Efficacy and Safety With Secukinumab</brief_title>
  <acronym>OPTIMISE</acronym>
  <official_title>Long Term Clear Skin Maintenance Treatment Optimization in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Multicenter, Open-label With Blinded-assessment, Comparative, 52 Week Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg s.c.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg
      s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c.
      every 4 weeks treatment with respect to maintaining a PASI 90 response rate at Week 52.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2015</start_date>
  <completion_date type="Actual">May 8, 2017</completion_date>
  <primary_completion_date type="Actual">March 14, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24</measure>
    <time_frame>Week 52</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key Secondary: PASI 90 Response Rate at Week 52 in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</measure>
    <time_frame>Week 52</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI 90 Response at Week 24</measure>
    <time_frame>week 52</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</measure>
    <time_frame>Week 52</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PASI in Participants With a PASI 90 Response at Week 24</measure>
    <time_frame>Baseline, Weeks 28, 32, 36, 40, 44, 48 and 52</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PASI in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</measure>
    <time_frame>Baseline, Weeks 28, 32, 36, 40, 44, 48 and 52</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DLQI in Participants With a PASI 90 Response at Week 24</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DLQI in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Work Productivity and Activity Impairment Questionnaire - Psoriasis (WPAI-PSO) Score in Participants With a PASI 90 Response at Week 24</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The WPAI-PSO is a self-administered questionnaire comprised of 6 questions about effects of psoriasis on the patient's ability to work and perform regular activities based on the previous 7 days. The questionnaire quantifies the number of hours the respondent was unable to work and evaluates how much the respondent's psoriasis affected productivity while working. For respondents who were not in paid employment, the questionnaire evaluated how much the respondent's psoriasis affects their ability to perform regular daily activities. Four outcomes were generated from the WPAI-PSO: % Absenteeism: percent work time missed due to health; % Presenteism: percent impairment while working due to health; % Total work productivity impairment: percent overall work impairment due to health; % Total activity impairment: percent activity impairment due to health for all respondents. First 3 outcomes applied to employed participants only. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI-PSO Score in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The WPAI-PSO is a self-administered questionnaire comprised of 6 questions about effects of psoriasis on the patient's ability to work and perform regular activities based on the previous 7 days. The questionnaire quantifies the number of hours the respondent was unable to work and evaluates how much the respondent's psoriasis affected productivity while working. For respondents who were not in paid employment, the questionnaire evaluated how much the respondent's psoriasis affects their ability to perform regular daily activities. Four outcomes were generated from the WPAI-PSO: % Absenteeism: percent work time missed due to health; % Presenteism: percent impairment while working due to health; % Total work productivity impairment: percent overall work impairment due to health; % Total activity impairment: percent activity impairment due to health for all respondents. First 3 outcomes applied to employed participants only. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pain, Itching and Scaling Score in Participants With a PASI 90 Response at Week 24</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Self-administered, 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; and Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours? Patients had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) and the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category. A negative change from baseline indicates improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pain, Itching and Scaling Score in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Self-administered, 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; and Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours? Patients had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) and the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category. A negative change from baseline indicates improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Quality of Life - 5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) in Participants With a PASI 90 Response at Week 24</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state.&quot; This resulted in a numeric value set ranging from 0 (=&quot;worst imaginable health state&quot;) up to 100 (=&quot;best imaginable health state&quot;). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EQ-5D VAS in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state.&quot; This resulted in a numeric value set ranging from 0 (=&quot;worst imaginable health state&quot;) up to 100 (=&quot;best imaginable health state&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EQ-5D Utility Index (Germany, United Kingdom (UK)) in Participants With a PASI 90 Response at Week 24</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The EQ-5D quantifies the health state of a patient for the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort &amp; anxiety/depression. In this study the EQ-5D-5L version has been used which evaluates each of these dimensions using the following 5 labels: no problems, slight problems, moderate problems, severe problems &amp; unable to/extreme problems. Based on the 5 dimensions, a summary score (utility index) was derived using country specific value sets evaluating the patient condition described by the outcome in the single dimensions. The EQ-5D-5L (in this trail) utility index based on the crosswalk value sets available from the EuroQol for Germany &amp; UK (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/) was calculated. A positive change from baseline indicates improvement.
A visual analogue scale was used within the EQ-5D measuring the health state of the patients, ranging from 0 (worst imaginable health state) up to 100 (best imaginable health state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EQ-5D Utility Index (Germany, UK) in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The EQ-5D quantifies the health state of a patient for the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. In the current study the EQ-5D-5L version has been used which evaluates each of these dimensions using the following five labels: &quot;no problems&quot;, &quot;slight problems&quot;, &quot;moderate problems&quot;, &quot;severe problems&quot; and &quot;unable to/extreme problems&quot;.
Based on the five dimensions, a summary score (utility index) was derived using country specific value sets evaluating the patient condition described by the outcome in the single dimensions. For this trial, the EQ-5D-5L utility index based on the crosswalk value sets available from the EuroQol for Germany and for UK (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/) was calculated.
A visual analogue scale (VAS) was used within the EQ-5D measuring the health state of the patients, ranging from 0 (=&quot;worst imaginable health state&quot;) up to 100 (=&quot;best imaginable health state&quot;).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16487</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Secukinumab 300mg in PASI 90 responders (every 4 weeks)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab 300mg in PASI 90 responders (longer intervals)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab 300mg in PASI 75-90 responders (shorter intervals)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.</description>
    <arm_group_label>Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)</arm_group_label>
    <arm_group_label>Secukinumab 300mg in PASI 75-90 responders (shorter intervals)</arm_group_label>
    <arm_group_label>Secukinumab 300mg in PASI 90 responders (every 4 weeks)</arm_group_label>
    <arm_group_label>Secukinumab 300mg in PASI 90 responders (longer intervals)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Chronic plaque-type psoriasis diagnosed for at least 6 months prior to Screening and
             candidate for systemic therapy.

          2. Moderate to severe psoriasis at Baseline as evidenced by:

               -  PASI ≥ 10 and

               -  IGA mod 2011 score of 3 or higher (based on a scale of 0 to 4) and

               -  BSA affected by plaque-type psoriasis of ≥ 10%.

        Main Exclusion Criteria:

          1. History of exposure to any biologic drug taken for the treatment of chronic plaque
             psoriasis or any other indication including but not limited to anti-tumor necrosis
             factor (TNF) alpha, anti interleukin (IL)12/23, or any anti-IL 17A or IL 17A receptor
             (IL 17AR) antibody.

          2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical
             classes.

          3. Forms of psoriasis other than chronic plaque-type (eg, pustular, erythrodermic and
             guttate psoriasis).

          4. Drug-induced psoriasis (ie, new onset or current exacerbation from beta-blockers,
             calcium channel inhibitors or lithium).

          5. Ongoing use of prohibited psoriasis treatments (eg, topical or systemic
             corticosteroids, ultraviolet (UV) therapy).

          6. Ongoing use of other non-psoriasis prohibited treatments. Washout periods detailed in
             the protocol have to be adhered to. All other prior non-psoriasis concomitant
             treatments must be at a stable dose as detailed in the protocol before initiation of
             study drug.

          7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive human chorionic gonadotropin (hCG) laboratory test (&gt; 5 mIU/mL).

          8. Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using effective methods of contraception during
             dosing of study drug and for 16 weeks after stopping study drug.

          9. Active ongoing inflammatory diseases other than psoriasis that might confound the
             evaluation of the benefit of secukinumab therapy.

         10. Underlying condition (including, but not limited to metabolic, hematologic, renal,
             hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal
             conditions) which, in the opinion of the Investigator, significantly immunocompromises
             the patient and/or places the patient at unacceptable risk for receiving an
             immunomodulatory therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A 1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jette</city>
        <state>Brussel</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Loverval</city>
        <zip>6280</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <state>BGR</state>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1404</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ivanic Grad</city>
        <zip>10310</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava Poruba</city>
        <state>Czech Republic</state>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 8</city>
        <state>Czech Republic</state>
        <zip>180 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arhus C</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hellerup</city>
        <zip>DK-2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Mans</city>
        <state>Cedex 09</state>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trevenans</city>
        <zip>90400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10783</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44793</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braunschweig</city>
        <zip>38100</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D 40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hanau</city>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osnabrueck</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pommelsbrunn</city>
        <zip>91224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stade</city>
        <zip>21682</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70178</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Larissa</city>
        <state>GR</state>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>546 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>161 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 43</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kecskemet</city>
        <state>Bacs Kiskun</state>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pecs</city>
        <zip>7632</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bolzano</city>
        <state>BZ</state>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daugavpils</city>
        <state>LVA</state>
        <zip>LV-5404</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <state>LVA</state>
        <zip>LV-1003</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ventspils</city>
        <state>LVA</state>
        <zip>LV-3601</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>1012</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LTU</state>
        <zip>LT 50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <state>LTU</state>
        <zip>92304</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LT</state>
        <zip>47144</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-07195</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breda</city>
        <state>CK</state>
        <zip>4818</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1817 MS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almere</city>
        <zip>1315 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergen op Zoom</city>
        <zip>4624 VT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geldrop</city>
        <zip>5664 EH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiderdorp</city>
        <zip>2353 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Voorburg</city>
        <zip>2275 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-045</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ossy</city>
        <zip>42 624</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60 529</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braga</city>
        <zip>4710243</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000 075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiria</city>
        <zip>2410-187</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200 319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <zip>4434 502</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454092</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostov on Don region</city>
        <zip>346880</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bojnice</city>
        <zip>972 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>841 04</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <zip>017 26</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svidnik</city>
        <zip>08901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villajoyosa</city>
        <state>Alicante</state>
        <zip>703570</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucia</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sant Joan Despi</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leon</city>
        <state>Castilla Y Leon</state>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona</city>
        <state>Catalunya</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Castellon</city>
        <state>Comunidad Valenciana</state>
        <zip>12005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas De G.C</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Sebastian de los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bilbao</city>
        <state>Pais Vasco</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alzira</city>
        <state>Valencia</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manises</city>
        <state>Valencia</state>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baracaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huesca</city>
        <zip>22004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mallorca</city>
        <zip>07500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pontevedra</city>
        <zip>36003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Falun</city>
        <zip>791 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malmo</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Geneve</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cliftonville</city>
        <state>Northampton</state>
        <zip>NN1 5BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cannock</city>
        <state>Staffordshire</state>
        <zip>WS11 2XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dudley</city>
        <state>West Midlands</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB7 5JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harrogate</city>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Ireland</country>
  </removed_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 31, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <results_first_submitted>May 4, 2018</results_first_submitted>
  <results_first_submitted_qc>February 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2019</results_first_posted>
  <last_update_submitted>February 12, 2019</last_update_submitted>
  <last_update_submitted_qc>February 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plaque, psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02409667/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 16, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02409667/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The screening period was up to 4 weeks and rescreening was allowed for an unlimited number of times. At the Screening Visit, every patient was registered in an Interactive Response Technology and the Investigator ensured that the patient fulfilled all the inclusion/exclusion criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Period 1: All Participants</title>
          <description>Participants received secukinumab 300 mg subcutaneous (s.c.) every 4 weeks for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Period 2: Group 1</title>
          <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Period 2: Group 2</title>
          <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 6 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Treatment Period 2: Group 3</title>
          <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks will be treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Treatment Period 2: Group 4</title>
          <description>Participants with moderate to severe plaque psoriasis, who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks, were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1, Baseline to Week 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1647"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1526"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal of informed consent</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2, Week 24 to Week 52)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="644"/>
                <participants group_id="P3" count="662"/>
                <participants group_id="P4" count="114"/>
                <participants group_id="P5" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="621"/>
                <participants group_id="P3" count="641"/>
                <participants group_id="P4" count="106"/>
                <participants group_id="P5" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of informed consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety set for Treatment Period 1 includes all subjects who took at least one dose of study treatment during this treatment period.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Period 1: All Participants</title>
          <description>Participants received secukinumab 300 mg subcutaneous (s.c.) every 4 weeks for 24 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1647"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="13.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="476"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1597"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
        <time_frame>Week 52</time_frame>
        <population>Full analysis set for Treatment Period 2 of PASI 90 responders (FAS-P90R): The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 1</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 2</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
          <population>Full analysis set for Treatment Period 2 of PASI 90 responders (FAS-P90R): The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="644"/>
                <count group_id="O2" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552"/>
                    <measurement group_id="O2" value="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The statistical null-hypothesis to be rejected in the primary analysis was that the odds ratio of maintaining a PASI 90 response for patients with secukinumab 4-weekly dosing versus patients on secukinumab 6-weekly dosing exceeds the non-inferiority margin of 1+δ.</non_inferiority_desc>
            <p_value>0.1499</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.44</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Key Secondary: PASI 90 Response Rate at Week 52 in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
        <time_frame>Week 52</time_frame>
        <population>FAS for Treatment Period 2 of PASI 75 responders who did not achieve a PASI 90 response (FAS-P75R): All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at the Week 24 visit, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after visit Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 3</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks will be treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 4</title>
            <description>Participants with moderate to severe plaque psoriasis, who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks, were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Key Secondary: PASI 90 Response Rate at Week 52 in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
          <population>FAS for Treatment Period 2 of PASI 75 responders who did not achieve a PASI 90 response (FAS-P75R): All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at the Week 24 visit, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after visit Week 24.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1013</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI 90 Response at Week 24</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
        <time_frame>week 52</time_frame>
        <population>Only participants from the FAS-P90R with evaluable data were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 1</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 2</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI 90 Response at Week 24</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
          <population>Only participants from the FAS-P90R with evaluable data were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="644"/>
                <count group_id="O2" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608"/>
                    <measurement group_id="O2" value="624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="597"/>
                    <measurement group_id="O2" value="588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="553"/>
                    <measurement group_id="O2" value="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378"/>
                    <measurement group_id="O2" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="609"/>
                    <count group_id="O2" value="628"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="564"/>
                    <measurement group_id="O2" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
        <time_frame>Week 52</time_frame>
        <population>Only participants from the FAS-P75R with evaluable data were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at the Week 24 visit, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after visit Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 3</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks will be treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 4</title>
            <description>Participants with moderate to severe plaque psoriasis, who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks, were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
          <population>Only participants from the FAS-P75R with evaluable data were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at the Week 24 visit, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after visit Week 24.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PASI in Participants With a PASI 90 Response at Week 24</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Weeks 28, 32, 36, 40, 44, 48 and 52</time_frame>
        <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and the post-baseline time point, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 1</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 2</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PASI in Participants With a PASI 90 Response at Week 24</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative change from baseline indicates improvement.</description>
          <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and the post-baseline time point, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="644"/>
                <count group_id="O2" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="642"/>
                    <count group_id="O2" value="656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="8.471"/>
                    <measurement group_id="O2" value="-19.9" spread="8.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="638"/>
                    <count group_id="O2" value="655"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="8.581"/>
                    <measurement group_id="O2" value="-19.8" spread="8.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="638"/>
                    <count group_id="O2" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.6" spread="8.439"/>
                    <measurement group_id="O2" value="-19.7" spread="8.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="632"/>
                    <count group_id="O2" value="649"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" spread="8.392"/>
                    <measurement group_id="O2" value="-19.6" spread="8.393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="623"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" spread="8.384"/>
                    <measurement group_id="O2" value="-19.6" spread="8.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="625"/>
                    <count group_id="O2" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" spread="8.472"/>
                    <measurement group_id="O2" value="-19.2" spread="8.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="610"/>
                    <count group_id="O2" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.4" spread="8.301"/>
                    <measurement group_id="O2" value="-19.2" spread="8.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 28</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0489</p_value>
            <method>ANCOVA</method>
            <param_type>Least square mean (LSM) estimate</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>-0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 32</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1073</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 36</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 40</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 44</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>ANCOVA</method>
            <param_type>LSM mean</param_type>
            <param_value>-0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PASI in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Weeks 28, 32, 36, 40, 44, 48 and 52</time_frame>
        <population>Participants from the FAS-P75R, who had evaluable data at both baseline and the post-baseline time point, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 3</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks will be treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 4</title>
            <description>Participants with moderate to severe plaque psoriasis, who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks, were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PASI in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative change from baseline indicates improvement.</description>
          <population>Participants from the FAS-P75R, who had evaluable data at both baseline and the post-baseline time point, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.1" spread="6.160"/>
                    <measurement group_id="O2" value="-16.3" spread="8.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.9" spread="6.002"/>
                    <measurement group_id="O2" value="-16.6" spread="7.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.1" spread="6.356"/>
                    <measurement group_id="O2" value="-16.6" spread="7.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.1" spread="6.908"/>
                    <measurement group_id="O2" value="-16.8" spread="8.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.1" spread="6.553"/>
                    <measurement group_id="O2" value="-16.6" spread="8.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" spread="6.246"/>
                    <measurement group_id="O2" value="-16.8" spread="8.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.5" spread="6.371"/>
                    <measurement group_id="O2" value="-16.6" spread="8.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 28</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1740</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 32</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0287</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 36</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1202</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 40</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1157</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 44</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3189</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0240</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0090</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DLQI in Participants With a PASI 90 Response at Week 24</title>
        <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and week 52, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 1</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 2</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DLQI in Participants With a PASI 90 Response at Week 24</title>
          <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
          <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and week 52, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="624"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.7" spread="7.325"/>
                    <measurement group_id="O2" value="-11.4" spread="7.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DLQI in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
        <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Participants from the FAS-P75R, who had evaluable data at both baseline and week 52, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 3</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks will be treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 4</title>
            <description>Participants with moderate to severe plaque psoriasis, who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks, were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DLQI in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
          <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
          <population>Participants from the FAS-P75R, who had evaluable data at both baseline and week 52, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="6.605"/>
                    <measurement group_id="O2" value="-9.72" spread="6.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0675</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>2.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Work Productivity and Activity Impairment Questionnaire - Psoriasis (WPAI-PSO) Score in Participants With a PASI 90 Response at Week 24</title>
        <description>The WPAI-PSO is a self-administered questionnaire comprised of 6 questions about effects of psoriasis on the patient's ability to work and perform regular activities based on the previous 7 days. The questionnaire quantifies the number of hours the respondent was unable to work and evaluates how much the respondent's psoriasis affected productivity while working. For respondents who were not in paid employment, the questionnaire evaluated how much the respondent's psoriasis affects their ability to perform regular daily activities. Four outcomes were generated from the WPAI-PSO: % Absenteeism: percent work time missed due to health; % Presenteism: percent impairment while working due to health; % Total work productivity impairment: percent overall work impairment due to health; % Total activity impairment: percent activity impairment due to health for all respondents. First 3 outcomes applied to employed participants only. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and week 52, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 1</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 2</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Productivity and Activity Impairment Questionnaire - Psoriasis (WPAI-PSO) Score in Participants With a PASI 90 Response at Week 24</title>
          <description>The WPAI-PSO is a self-administered questionnaire comprised of 6 questions about effects of psoriasis on the patient's ability to work and perform regular activities based on the previous 7 days. The questionnaire quantifies the number of hours the respondent was unable to work and evaluates how much the respondent's psoriasis affected productivity while working. For respondents who were not in paid employment, the questionnaire evaluated how much the respondent's psoriasis affects their ability to perform regular daily activities. Four outcomes were generated from the WPAI-PSO: % Absenteeism: percent work time missed due to health; % Presenteism: percent impairment while working due to health; % Total work productivity impairment: percent overall work impairment due to health; % Total activity impairment: percent activity impairment due to health for all respondents. First 3 outcomes applied to employed participants only. A negative change from baseline indicates improvement.</description>
          <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and week 52, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="644"/>
                <count group_id="O2" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absenteeism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="356"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.70" spread="19.590"/>
                    <measurement group_id="O2" value="-1.99" spread="19.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                    <count group_id="O2" value="348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.1" spread="25.968"/>
                    <measurement group_id="O2" value="-23.0" spread="26.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total activity impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.3" spread="27.850"/>
                    <measurement group_id="O2" value="-23.2" spread="29.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work productivity loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="546"/>
                    <count group_id="O2" value="550"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.9" spread="29.392"/>
                    <measurement group_id="O2" value="-28.6" spread="27.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Absenteeism</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2101</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Presenteeism</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2971</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.93</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total activity impairment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5499</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.59</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0758</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.28</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI-PSO Score in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
        <description>The WPAI-PSO is a self-administered questionnaire comprised of 6 questions about effects of psoriasis on the patient's ability to work and perform regular activities based on the previous 7 days. The questionnaire quantifies the number of hours the respondent was unable to work and evaluates how much the respondent's psoriasis affected productivity while working. For respondents who were not in paid employment, the questionnaire evaluated how much the respondent's psoriasis affects their ability to perform regular daily activities. Four outcomes were generated from the WPAI-PSO: % Absenteeism: percent work time missed due to health; % Presenteism: percent impairment while working due to health; % Total work productivity impairment: percent overall work impairment due to health; % Total activity impairment: percent activity impairment due to health for all respondents. First 3 outcomes applied to employed participants only. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Participants from the FAS-P75R, who had evaluable data at both baseline and week 52, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 3</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks will be treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 4</title>
            <description>Participants with moderate to severe plaque psoriasis, who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks, were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI-PSO Score in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
          <description>The WPAI-PSO is a self-administered questionnaire comprised of 6 questions about effects of psoriasis on the patient's ability to work and perform regular activities based on the previous 7 days. The questionnaire quantifies the number of hours the respondent was unable to work and evaluates how much the respondent's psoriasis affected productivity while working. For respondents who were not in paid employment, the questionnaire evaluated how much the respondent's psoriasis affects their ability to perform regular daily activities. Four outcomes were generated from the WPAI-PSO: % Absenteeism: percent work time missed due to health; % Presenteism: percent impairment while working due to health; % Total work productivity impairment: percent overall work impairment due to health; % Total activity impairment: percent activity impairment due to health for all respondents. First 3 outcomes applied to employed participants only. A negative change from baseline indicates improvement.</description>
          <population>Participants from the FAS-P75R, who had evaluable data at both baseline and week 52, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absenteeism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="12.990"/>
                    <measurement group_id="O2" value="-3.45" spread="18.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.9" spread="28.377"/>
                    <measurement group_id="O2" value="-22.1" spread="26.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total activity impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.1" spread="28.657"/>
                    <measurement group_id="O2" value="-21.7" spread="29.905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work productivity loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.2" spread="28.824"/>
                    <measurement group_id="O2" value="-22.5" spread="25.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Absenteeism</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4156</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.71</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Presenteeism</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8619</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.59</ci_lower_limit>
            <ci_upper_limit>7.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total activity impairment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6139</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.31</ci_lower_limit>
            <ci_upper_limit>10.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Work productivity loss</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5674</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.16</ci_lower_limit>
            <ci_upper_limit>7.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pain, Itching and Scaling Score in Participants With a PASI 90 Response at Week 24</title>
        <description>Self-administered, 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; and Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours? Patients had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) and the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category. A negative change from baseline indicates improvement</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and week 52, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 1</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 2</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pain, Itching and Scaling Score in Participants With a PASI 90 Response at Week 24</title>
          <description>Self-administered, 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; and Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours? Patients had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) and the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category. A negative change from baseline indicates improvement</description>
          <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and week 52, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="644"/>
                <count group_id="O2" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="495"/>
                    <count group_id="O2" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.56" spread="2.771"/>
                    <measurement group_id="O2" value="-4.17" spread="2.2727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="590"/>
                    <count group_id="O2" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.59" spread="2.885"/>
                    <measurement group_id="O2" value="-5.20" spread="2.985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="598"/>
                    <count group_id="O2" value="610"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.05" spread="2.659"/>
                    <measurement group_id="O2" value="-5.73" spread="2.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1219</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Itching</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Scaling</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pain, Itching and Scaling Score in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
        <description>Self-administered, 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; and Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours? Patients had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) and the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category. A negative change from baseline indicates improvement</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Participants from the FAS-P75R, who had evaluable data at both baseline and week 52, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 3</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks will be treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 4</title>
            <description>Participants with moderate to severe plaque psoriasis, who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks, were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pain, Itching and Scaling Score in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
          <description>Self-administered, 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; and Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours? Patients had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) and the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category. A negative change from baseline indicates improvement</description>
          <population>Participants from the FAS-P75R, who had evaluable data at both baseline and week 52, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.59" spread="2.754"/>
                    <measurement group_id="O2" value="-3.68" spread="3.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.13" spread="2.883"/>
                    <measurement group_id="O2" value="-4.49" spread="3.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scaling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.66" spread="2.960"/>
                    <measurement group_id="O2" value="-5.40" spread="2.899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6457</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Itching</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6136</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Scaling</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0203</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Quality of Life - 5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) in Participants With a PASI 90 Response at Week 24</title>
        <description>A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state.&quot; This resulted in a numeric value set ranging from 0 (=&quot;worst imaginable health state&quot;) up to 100 (=&quot;best imaginable health state&quot;). A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and week 52, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 1</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 2</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Quality of Life - 5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) in Participants With a PASI 90 Response at Week 24</title>
          <description>A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state.&quot; This resulted in a numeric value set ranging from 0 (=&quot;worst imaginable health state&quot;) up to 100 (=&quot;best imaginable health state&quot;). A positive change from baseline indicates improvement.</description>
          <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and week 52, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="603"/>
                <count group_id="O2" value="620"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.34" spread="23.296"/>
                    <measurement group_id="O2" value="21.24" spread="22.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>3.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EQ-5D VAS in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
        <description>A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state.&quot; This resulted in a numeric value set ranging from 0 (=&quot;worst imaginable health state&quot;) up to 100 (=&quot;best imaginable health state&quot;).</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Participants from the FAS-P75R, who had evaluable data at both baseline and week 52, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 3</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks will be treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 4</title>
            <description>Participants with moderate to severe plaque psoriasis, who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks, were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EQ-5D VAS in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
          <description>A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state.&quot; This resulted in a numeric value set ranging from 0 (=&quot;worst imaginable health state&quot;) up to 100 (=&quot;best imaginable health state&quot;).</description>
          <population>Participants from the FAS-P75R, who had evaluable data at both baseline and week 52, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.86" spread="20.099"/>
                    <measurement group_id="O2" value="18.92" spread="19.855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2823</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.55</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EQ-5D Utility Index (Germany, United Kingdom (UK)) in Participants With a PASI 90 Response at Week 24</title>
        <description>The EQ-5D quantifies the health state of a patient for the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort &amp; anxiety/depression. In this study the EQ-5D-5L version has been used which evaluates each of these dimensions using the following 5 labels: no problems, slight problems, moderate problems, severe problems &amp; unable to/extreme problems. Based on the 5 dimensions, a summary score (utility index) was derived using country specific value sets evaluating the patient condition described by the outcome in the single dimensions. The EQ-5D-5L (in this trail) utility index based on the crosswalk value sets available from the EuroQol for Germany &amp; UK (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/) was calculated. A positive change from baseline indicates improvement.
A visual analogue scale was used within the EQ-5D measuring the health state of the patients, ranging from 0 (worst imaginable health state) up to 100 (best imaginable health state).</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and week 52, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 1</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 2</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EQ-5D Utility Index (Germany, United Kingdom (UK)) in Participants With a PASI 90 Response at Week 24</title>
          <description>The EQ-5D quantifies the health state of a patient for the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort &amp; anxiety/depression. In this study the EQ-5D-5L version has been used which evaluates each of these dimensions using the following 5 labels: no problems, slight problems, moderate problems, severe problems &amp; unable to/extreme problems. Based on the 5 dimensions, a summary score (utility index) was derived using country specific value sets evaluating the patient condition described by the outcome in the single dimensions. The EQ-5D-5L (in this trail) utility index based on the crosswalk value sets available from the EuroQol for Germany &amp; UK (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/) was calculated. A positive change from baseline indicates improvement.
A visual analogue scale was used within the EQ-5D measuring the health state of the patients, ranging from 0 (worst imaginable health state) up to 100 (best imaginable health state).</description>
          <population>Only participants from the FAS-P90R, who had evaluable data at both baseline and week 52, were analyzed. The FAS-P90R included all participants who were rated as PASI 90 responders at the Week 24 visit, randomized to treatment groups 1 or 2 and received at least one dose of study drug at or after visit Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="623"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.200"/>
                    <measurement group_id="O2" value="0.13" spread="0.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.250"/>
                    <measurement group_id="O2" value="0.22" spread="0.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Germany</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0861</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>UK</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0117</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EQ-5D Utility Index (Germany, UK) in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
        <description>The EQ-5D quantifies the health state of a patient for the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. In the current study the EQ-5D-5L version has been used which evaluates each of these dimensions using the following five labels: &quot;no problems&quot;, &quot;slight problems&quot;, &quot;moderate problems&quot;, &quot;severe problems&quot; and &quot;unable to/extreme problems&quot;.
Based on the five dimensions, a summary score (utility index) was derived using country specific value sets evaluating the patient condition described by the outcome in the single dimensions. For this trial, the EQ-5D-5L utility index based on the crosswalk value sets available from the EuroQol for Germany and for UK (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/) was calculated.
A visual analogue scale (VAS) was used within the EQ-5D measuring the health state of the patients, ranging from 0 (=&quot;worst imaginable health state&quot;) up to 100 (=&quot;best imaginable health state&quot;).</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Participants from the FAS-P75R, who had evaluable data at both baseline and week 52, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period 2: Group 3</title>
            <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks will be treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period 2: Group 4</title>
            <description>Participants with moderate to severe plaque psoriasis, who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks, were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EQ-5D Utility Index (Germany, UK) in Participants With a PASI Response of ≥75 to &lt;90 at Week 24</title>
          <description>The EQ-5D quantifies the health state of a patient for the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. In the current study the EQ-5D-5L version has been used which evaluates each of these dimensions using the following five labels: &quot;no problems&quot;, &quot;slight problems&quot;, &quot;moderate problems&quot;, &quot;severe problems&quot; and &quot;unable to/extreme problems&quot;.
Based on the five dimensions, a summary score (utility index) was derived using country specific value sets evaluating the patient condition described by the outcome in the single dimensions. For this trial, the EQ-5D-5L utility index based on the crosswalk value sets available from the EuroQol for Germany and for UK (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/) was calculated.
A visual analogue scale (VAS) was used within the EQ-5D measuring the health state of the patients, ranging from 0 (=&quot;worst imaginable health state&quot;) up to 100 (=&quot;best imaginable health state&quot;).</description>
          <population>Participants from the FAS-P75R, who had evaluable data at both baseline and week 52, were analyzed. FAS-P75R: All participants who were rated as PASI 75 responders but did not achieve a PASI 90 response at Week 24, were randomized to treatment groups 3 or 4 and who received at least one dose of study drug at or after Week 24.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.164"/>
                    <measurement group_id="O2" value="0.13" spread="0.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.206"/>
                    <measurement group_id="O2" value="0.21" spread="0.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Germany</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1852</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>UK</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2203</p_value>
            <method>ANCOVA</method>
            <param_type>LSM estimate</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 52</time_frame>
      <desc>The Adverse Events (AE) dataset has MedDRA version 19.1 (5345 records) and 20.0 (1272 records).</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Period 1: All Participants</title>
          <description>Participants received secukinumab 300 mg subcutaneous (s.c.) every 4 weeks for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Treatment Period 2: Group 1</title>
          <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Treatment Period 2: Group 2</title>
          <description>Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 6 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Treatment Period 2: Group 3</title>
          <description>Participants with moderate to severe plaque psoriasis who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks will be treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 4 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Treatment Period 2: Group 4</title>
          <description>Participants with moderate to severe plaque psoriasis, who had reached PASI 75 to &lt;90 response after 24 weeks of treatment with secukinumab 300 mg s.c. every 4 weeks, were treated with Secukinumab 300 mg s.c. from week 24 until Week 52 every 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic liver disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oral fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Peripheral sensorimotor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Peyronie's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lichenoid keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Alcohol use</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="884" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="272" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="288" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="60" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="368" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Erythrodermic psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="1647"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="644"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="662"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

